SETTING: All Brazilian states. OBJECTIVES: To assess the determinants of @entity378 ( @entity378 ) in @entity1 undergoing directly observed therapy (DOT) and the impact of DOT on treatment outcomes. DESIGN: This is a cross-sectional study among @entity378 @entity1 aged    18 years conducted in 2011. The primary outcome was the status of DOT received, while the secondary was the outcome of anti- @entity378 treatment. RESULTS: In 2011, 35   775 (38.3%) subjects received DOT. The odds of receiving DOT were higher in @entity1 with the following characteristics: brown/mestizo @entity1 (OR 1.18, 95%CI 1.14-1.22) and those of other ethnic groups (OR 2.01, 95%CI 1.79-2.27) compared to Whites, @entity285 users (OR 1.37, 95%CI 1.28-1.47) and those with @entity146 (OR 1.88, 95%CI 1.54-2.29). The odds of receiving DOT were lower in @entity1 @entity465 virus positive @entity1 (OR 0.64, 95%CI 0.60-0.68). @entity1 who did not receive DOT were more likely to default from anti- @entity378 treatment (OR 0.62, 95%CI 0.57-0.66), die due to @entity378 (OR 0.68, 95%CI 0.61-0.77) and to have unknown treatment outcomes (OR 0.71, 95%CI 0.66-0.76). The adjusted preventable fraction of DOT in the reduction of unfavorable outcomes was 25%. CONCLUSION: Sociodemographic and clinical characteristics are determinants of anti- @entity378 treatment outcomes in @entity1 undergoing DOT; DOT use led to a 25% reduction in unfavorable outcomes.

Directly observed therapy of XXXX in Brazil: associated determinants and impact on treatment outcome.

@entity1 :: ('9606', 'Species') :: ['Patients', 'human', 'patients'] @entity146 :: ('MESH:D001523', 'Disease') :: ['mental disorders'] @entity465 :: ('MESH:D007153', 'Disease') :: ['immunodeficiency'] @entity378 :: ('MESH:D014376', 'Disease') :: ['TB', 'tuberculosis'] @entity285 :: ('D000431', 'Chemical') :: ['alcohol']
@entity378 :: (MESH:D014376,Disease) :: ['tuberculosis']
